title: Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.
abstract: Trastuzumab is a monoclonal antibody that is used in the treatment of breast cancer. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2) receptor on breast cancer cells that express this tyrosine kinase receptor. These cancers are referred to as HER2-positive breast cancer. The original studies of trastuzumab showed improved survival in metastatic breast cancer; however, resistance often develops. In the adjuvant setting, women often progress despite therapy that includes trastuzumab. Antibody-drug conjugates are a new class of powerful drugs designed to target high-dose chemotherapy directly to the cancer cells. Trastuzumab emtansine is one of these antibody-drug conjugates and was the first Food and Drug Administration approved drug for a solid tumor. Emtansine is a potent antimicrotubule agent. Trastuzumab is used to target this potent chemotherapy agent directly to the HER2-expressing cancer cells. This review article will summarize the evidence from the preclinical studies, summarize evidence from the clinical trials, discuss current clinical trials, discuss current approval of trastuzumab emtansine, and discuss future directions of research.
authors.affiliation: Division of Hematology, Oncology, and Transplant. University of Minnesota, Minneapolis, MN, USA.
authors.forename: Drew R
authors.initials: DR
authors.lastname: Oostra
authors.affiliation: Division of Medical Oncology, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
authors.forename: Erin R
authors.initials: ER
authors.lastname: Macrae
keywords: HER2; Kadcyla®; T-DM1; breast cancer; trastuzumab emtansine
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3234-41
references.pmid: 22649126
references.citation: Mol Med. 2013 Jan 22;18:1473-9
references.pmid: 23196784
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references.pmid: 20124187
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Cancer Res. 2008 Nov 15;68(22):9280-90
references.pmid: 19010901
references.citation: J Clin Oncol. 2010 Jan 1;28(1):92-8
references.pmid: 19933921
references.citation: Cancer. 2012 Dec 1;118(23):5733-40
references.pmid: 22648179
references.citation: Clin Cancer Res. 2010 Oct 1;16(19):4769-78
references.pmid: 20805300
references.citation: Clin Cancer Res. 2016 Aug 1;22(15):3755-63
references.pmid: 26920887
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2698-704
references.pmid: 20421541
references.citation: Oncologist. 2009 Apr;14(4):320-68
references.pmid: 19346299
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7968-73
references.pmid: 12060743
references.citation: Pharmgenomics Pers Med. 2013 Dec 16;7:1-19
references.pmid: 24403841
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2585-92
references.pmid: 22689807
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: J Neurooncol. 2014 Jan;116(1):205-6
references.pmid: 24065570
references.citation: J Clin Oncol. 2004 Mar 15;22(6):1063-70
references.pmid: 15020607
references.citation: Breast Cancer Res Treat. 2011 Jul;128(2):347-56
references.pmid: 20730488
references.citation: J Clin Oncol. 2013 Mar 20;31(9):1157-63
references.pmid: 23382472
references.citation: Breast. 2013 Aug;22(4):525-31
references.pmid: 23352568
references.citation: Mol Cancer Ther. 2012 May;11(5):1133-42
references.pmid: 22408268
references.citation: Ann Oncol. 2013 Jun;24(6):1526-33
references.pmid: 23463626
references.citation: Clin Cancer Res. 2001 Jun;7(6):1490-6
references.pmid: 11410481
references.citation: Ann Oncol. 2012 Jan;23(1):93-97
references.pmid: 21531783
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2190-6
references.pmid: 22614995
references.citation: Protein Sci. 2005 Sep;14(9):2436-46
references.pmid: 16081651
references.citation: Cancer Chemother Pharmacol. 2012 May;69(5):1229-40
references.pmid: 22271209
references.citation: Mol Cell Biol. 1989 Mar;9(3):1165-72
references.pmid: 2566907
references.citation: Blood. 2012 Jul 19;120(3):560-8
references.pmid: 22510871
references.citation: N Engl J Med. 2007 Jul 5;357(1):39-51
references.pmid: 17611206
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
references.pmid: 1350088
references.citation: Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
references.pmid: 11597398
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: J Clin Oncol. 2012 May 10;30(14):1712-4
references.pmid: 22393085
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: Nature. 1977 Dec 22-29;270(5639):721-2
references.pmid: 593392
references.citation: J Clin Oncol. 2011 Feb 1;29(4):351-4
references.pmid: 21172881
references.citation: J Clin Oncol. 2011 Feb 1;29(4):398-405
references.pmid: 21172893
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153